Product Program year 2023 Source: CMS Open Payments

Luxturna

Drug Ophthalmology

NDC 71394-415-01

Open in the dashboard

General payments

$87,948

28 payments

Research payments

$0

0 payments

Through program year 2023, $87,948 in general payments and $0 in research payments were reported against Luxturna (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2023 General $23,459 7
2022 General $14,650 5
2020 General $49,839 16

Breakdown

Who paid General payments · program years 2020–2023
  1. Novartis Pharma AG $87,948 28 payments
Top recipients General payments · program year 2023
  1. Stephen Russell Ophthalmology · Iowa City, IA $16,913 72% · 3 payments
  2. Aaron Nagiel Ophthalmology · Ventura, CA $6,150 26% · 1 payment
  3. Bart Leroy Ophthalmology · Philadelphia, PA $397 2% · 3 payments

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Ophthalmology $23,459 100% · 3 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. Iowa $16,913 72% · 1 recipient
  2. California $6,150 26% · 1 recipient
  3. Pennsylvania $397 2% · 1 recipient

Each share is of general payments naming this product in 2023 where a state was reported.

28 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record